LOS ANGELES, July 20, 2026
Armata Pharmaceuticals, Inc. has announced significant clinical, regulatory, manufacturing, and operational progress supporting the planned initiation of its Phase III superiority trial for AP-SA02, the company’s investigational bacteriophage therapy for the adjunct treatment of complicated Staphylococcus aureus bacteremia. The late clinical-stage biotechnology company confirmed that it has submitted the complete Phase III clinical protocol and comprehensive responses addressing all feedback received from the U.S. Food and Drug Administration (FDA) following its End-of-Phase II (EOP2) meeting. In parallel, Armata has completed four engineering manufacturing runs at its cGMP facility, bringing the company another step closer to producing clinical trial material for the pivotal study. These milestones reinforce Armata’s strategy to advance one of the most promising phage-based therapeutics for combating antibiotic-resistant bacterial infections, with the Phase III study expected to begin during the second half of 2026.
FDA Regulatory Milestones Strengthen Phase III Readiness
Armata reported that it has successfully completed a series of key regulatory submissions designed to support the transition of AP-SA02 into late-stage clinical development. The company submitted the full Phase III superiority study protocol to the FDA, incorporating every recommendation outlined during the agency’s End-of-Phase II review. In addition, Armata provided complete responses covering clinical development, Chemistry, Manufacturing and Controls (CMC), and other regulatory topics requested by the FDA. These submissions are intended to ensure regulatory alignment before initiating the pivotal study, which is designed to support a future Biologics License Application (BLA). The Phase III trial will evaluate AP-SA02 as an adjunct to standard antibiotic therapy in patients with methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) bacteremia, two serious bloodstream infections associated with significant morbidity, mortality, and growing antimicrobial resistance.
Manufacturing Progress Supports Late-Stage Clinical Development
Beyond regulatory achievements, Armata has continued expanding its manufacturing capabilities to support commercial-scale development. The company completed four engineering production runs of AP-SA02 at its in-house current Good Manufacturing Practice (cGMP) manufacturing facility in Los Angeles. The next planned milestone involves manufacturing clinical-grade trial material required for the Phase III study. Armata also confirmed continued financial support through its collaboration with the U.S. Department of Defense (DoD), receiving an additional $2.5 million, increasing total funding under the existing award to $28.7 million. The additional funding will help accelerate final Phase III preparation activities, while the company continues discussions regarding potential future government support alongside evaluating additional financing opportunities to execute the pivotal clinical program.
Advertisement
Bacteriophage Therapy Targets Antibiotic Resistance Crisis
AP-SA02 is a fixed multi-phage cocktail developed specifically to target Staphylococcus aureus, including infections caused by both MSSA and MRSA. Unlike conventional antibiotics, bacteriophage therapy uses naturally occurring viruses that selectively infect and eliminate disease-causing bacteria, offering a promising strategy to address the growing global challenge of antibiotic resistance. AP-SA02 has already received both Fast Track and Qualified Infectious Disease Product (QIDP) designations from the FDA, reflecting its potential to address significant unmet medical needs. Positive findings from the earlier Phase Ib/IIa diSArm clinical study, presented at IDWeek 2025, demonstrated encouraging safety and clinical activity when administered alongside standard antibiotic treatment. With regulatory submissions completed, manufacturing progressing, and leadership strengthened through the appointment of David House as Chief Financial Officer, Armata is positioned to enter a pivotal Phase III program that could represent a major advancement in the development of next-generation bacteriophage therapeutics for life-threatening bacterial bloodstream infections.
Source: Armata Pharmaceuticals press release
